Jack Cumming, Hologic's CEO, will discuss the impact of Hologic's 3D mammography technology and efforts to raise awareness of breast cancer during the month of October

BEDFORD, Mass., Oct. 1, 2013/PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced that Jack W. Cumming, Hologic's President and Chief Executive Officer, will preside over the NASDAQ Stock Market Opening Bell Ceremony marking the start of a month long effort to raise awareness of breast cancer and the importance of breast cancer screening. This is the eighth year that Hologic has been selected to participate in the NASDAQ opening bell ceremonies celebrating the start of Breast Cancer Awareness Month.

In his opening remarks, Mr. Cumming will focus on the value of Hologic's 3D mammography (breast tomosynthesis) in finding more invasive cancers and decreasing unnecessary recalls.   

Hologic's 3D Mammography Technology

3D mammography (breast tomosynthesis) technology detects invasive cancers earlier when the disease is easiest to treat. Unlike conventional 2D mammography where the presence of overlapping breast tissue can make it more difficult to detect cancer, Hologic's 3D mammography technology is designed to allow doctors to see the breast more clearly, particularly for women with dense breasts.  As a result, fewer women are called back for additional testing due to false positive results. Large clinical studies in Europeand the U.S. report that Hologic's 3D mammography technology significantly reduces recall rates while simultaneously improving cancer detection.

  • Clinical research shows that the Hologic 3D mammogram finds 40% more invasive cancers than conventional 2D mammography.
  • Clearer, more detailed images from the Hologic 3D mammogram give doctors the confidence to significantly reduce recall rates by up to 40%, minimizing the inconvenience, cost and anxiety that women feel when asked to return for unnecessary follow-up tests.

Hologic is the only manufacturer to receive FDA approval for 3D mammography and is the largest breast tomosynthesis vendor worldwide. More than 3 million women will be screened this year with this groundbreaking technology.

Webcast Information:

The Hologic NASDAQ Stock Market Opening Bell Ceremony will be aired live at http://www.nasdaq.com/reference/marketsite_about.aspx (access this by clicking on the MarketSite live webcam) and will also be aired with closed captioning on the NASDAQ MarketSite Tower in Times Square. A video of the Opening Bell ceremony will be archived for one year on the NASDAQ site.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United Statesand/or other countries.

Forward-Looking Statement Disclaimer:

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic digital mammography systems. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Investor and Media Contacts:

Deborah R. Gordon

Marianne McMorrow

Vice President, Investor Relations

Global PR and Advertising Publicist

(781) 999-7716

(781) 999-7723

deborah.gordon@hologic.com

marianne.mcmorrow@hologic.com



Al Kildani


Senior Director, Investor Relations


(858) 410-8653


al.kildani@hologic.com


SOURCE Hologic, Inc.

distributed by